MARKET

ABBV

ABBV

AbbVie
NYSE

Real-time Quotes | Nasdaq Last Sale

107.33
-1.36
-1.25%
After Hours: 107.00 -0.33 -0.31% 19:54 02/25 EST
OPEN
108.48
PREV CLOSE
108.69
HIGH
109.30
LOW
107.07
VOLUME
6.24M
TURNOVER
--
52 WEEK HIGH
113.41
52 WEEK LOW
62.55
MARKET CAP
189.53B
P/E (TTM)
39.61
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
7th Circuit urged to revive 'patent minefield' suit over AbbVie's Humira
Purchasers of AbbVie Inc's arthritis drug Humira on Thursday urged a federal appeals court to revive their antitrust lawsuit accusing the company of shielding the drug behind a "minefield" of meritless patents.
Reuters · 4h ago
AbbVie's Allergan Files US Application AGN-190584 For Presbyopia
Benzinga · 6h ago
Thumb Arthritis Market 2020 Receives a Rapid Boost in Economy due to High Emerging Demands by Forecast to 2023
Heraldkeepers · 8h ago
Autoimmune Disorder Therapies: Global Markets
Feb 25, 2021 (Heraldkeepers) -- COMTEX_381727432/2582/2021-02-25T12:08:02 Is there a problem with this press release? Contact the source provider Comtex at...
Heraldkeepers · 8h ago
Pharmaceuticals for Women’s Health: Global Markets
Heraldkeepers · 9h ago
Acne Drugs Market Research Report by Acne Type, by Drug Class, by Drug Type, by Route of Administration - Global Forecast to 2025 - Cumulative Impact of COVID-19
New York, Feb 25, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Acne...
GlobeNewswire · 10h ago
Harvest Portfolios Group Inc. Announces $9.3 million Overnight Offering for Big Pharma Split Corp.
TORONTO, Feb 25, 2021 (GLOBE NEWSWIRE via COMTEX) -- TORONTO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Harvest Portfolios Group Inc. ("Harvest") is pleased to...
GlobeNewswire · 10h ago
BRIEF-Allergan, An Abbvie Company, Submits New Drug Application For Investigational AGN-190584 For The Treatment Of Presbyopia
reuters.com · 11h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ABBV. Analyze the recent business situations of AbbVie through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 23 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ABBV stock price target is 120.67 with a high estimate of 140.00 and a low estimate of 97.00.
EPS
Institutional Holdings
Institutions: 3.29K
Institutional Holdings: 1.26B
% Owned: 71.47%
Shares Outstanding: 1.77B
TypeInstitutionsShares
Increased
1.06K
45.03M
New
378
8.11M
Decreased
847
71.94M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.83%
Pharmaceuticals & Medical Research
-1.34%
Key Executives
Chairman/Chief Executive Officer/Director
Richard Gonzalez
President/Vice Chairman - Management
Michael Severino
Vice Chairman - Management
Carlos Alban
Vice Chairman - Management
Laura Schumacher
Chief Financial Officer/Senior Vice President
Robert Michael
Chief Human Resource Officer/Executive Vice President
Timothy Richmond
Executive Vice President - Finance
William Chase
Executive Vice President
Henry Gosebruch
Executive Vice President
Azita Saleki-Gerhardt
Senior Vice President
Nicholas Donoghoe
Senior Vice President
Jeffrey Stewart
Vice President/Controller
Brian Durkin
Lead Director/Independent Director
Glenn Tilton
Independent Director
Robert Alpern
Independent Director
Roxanne Austin
Independent Director
William Burnside
Independent Director
Thomas Freyman
Independent Director
Brett Hart
Independent Director
Edward Liddy
Independent Director
Melody Meyer
Independent Director
Edward Rapp
Independent Director
Rebecca Roberts
Independent Director
Frederick Waddell
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
02/18/2021
Dividend USD 1.3
04/14/2021
10/30/2020
Dividend USD 1.3
01/14/2021
09/11/2020
Dividend USD 1.18
10/14/2020
06/17/2020
Dividend USD 1.18
07/14/2020
02/20/2020
Dividend USD 1.18
04/14/2020
11/01/2019
Dividend USD 1.18
01/14/2020
09/06/2019
Dividend USD 1.07
10/11/2019
06/20/2019
Dividend USD 1.07
07/12/2019
02/21/2019
Dividend USD 1.07
04/12/2019
11/02/2018
Dividend USD 1.07
01/14/2019
09/07/2018
Dividend USD 0.96
10/12/2018
06/14/2018
Dividend USD 0.96
07/12/2018
02/15/2018
Dividend USD 0.96
04/12/2018
10/26/2017
Dividend USD 0.71
01/11/2018
09/08/2017
Dividend USD 0.64
10/12/2017
06/23/2017
Dividend USD 0.64
07/12/2017
02/17/2017
Dividend USD 0.64
04/11/2017
10/31/2016
Dividend USD 0.64
01/11/2017
09/09/2016
Dividend USD 0.57
10/12/2016
06/16/2016
Dividend USD 0.57
07/13/2016
02/18/2016
Dividend USD 0.57
04/13/2016
10/30/2015
Dividend USD 0.57
01/13/2016
09/11/2015
Dividend USD 0.51
10/13/2015
06/19/2015
Dividend USD 0.51
07/13/2015
02/19/2015
Dividend USD 0.51
04/13/2015
10/21/2014
Dividend USD 0.49
01/13/2015
09/19/2014
Dividend USD 0.42
10/10/2014
06/19/2014
Dividend USD 0.42
07/11/2014
02/20/2014
Dividend USD 0.42
04/11/2014
12/12/2013
Dividend USD 0.4
01/13/2014
09/19/2013
Dividend USD 0.4
10/10/2013
06/20/2013
Dividend USD 0.4
07/11/2013
About ABBV
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Webull offers kinds of AbbVie Inc stock information, including NYSE:ABBV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABBV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABBV stock methods without spending real money on the virtual paper trading platform.